Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Abpro Holdings ( (ABP) ) just unveiled an announcement.
Abpro Holdings announced the successful closing of its business combination with Atlantic Coastal Acquisition Corp II, marked by a Nasdaq bell ringing ceremony. The company also raised $10 million in gross proceeds and has agreements to secure additional funding, which will support the advancement of its antibody therapy pipeline. This milestone enhances Abpro’s financial flexibility and positions it well for future growth in developing novel treatments for oncology, ophthalmology, and infectious diseases. The company aims to accelerate its pipeline towards clinical trials, creating potential value for stakeholders and improving patient outcomes.
More about Abpro Holdings
Abpro Holdings is a biotechnology company based in Woburn, Massachusetts, focused on developing next-generation antibody therapies to treat severe and life-threatening diseases. The company is advancing a pipeline targeting cancers such as HER2+ breast, gastric, colorectal, non-HER2+ gastric and liver cancer, as well as wet age-related macular degeneration, diabetic macular edema, and infectious diseases. Abpro’s proprietary DiversImmune® platform is utilized to develop these therapies, and it has partnered with Celltrion, a leading South Korean biotechnology firm, to advance its T-cell engager ABP 102.
YTD Price Performance: -85.61%
Average Trading Volume: 34,875
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $81.4M
For an in-depth examination of ABP stock, go to TipRanks’ Stock Analysis page.
